Drugs / Tafolecimab
Trials 19 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 26 trials | ||||||
| Phase 2 | NCT07621562 | Jun 2026 → Sep 2027 expected | gastric adenocarcinoma, gastroesophageal junction adenocarcinoma | First Affiliated Hospital of Zhejiang University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07061535 | Jul 2025 → Aug 2027 expected | small cell lung carcinoma | Second Affiliated Hospital, School of Medicine, Zhejiang University | Recruiting | No outcome recorded |
| Phase 2 | NCT07014215 | Jun 2025 → May 2027 expected | non-small cell lung carcinoma | Anhui Provincial Cancer Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06421298 | May 2024 → May 2027 expected | lung cancer | Jinghui Wang | Recruiting | No outcome recorded |
| Phase 2 | NCT06304987 | Apr 2024 → Apr 2026 | — | Beijing Friendship Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT03815812 | Mar → Dec 2019 | hyperlipidemia | Innovent Biologics (Suzhou) Co. Ltd. | Completed | No outcome recorded |
| Phase 2/32 trials | ||||||
| Phase 2/3 | NCT04948008 | Nov 2019 → Jul 2020 | homozygous familial hypercholesterolemia | Shenzhen People's Hospital | Unknown | No outcome recorded |
| Phase 2/3 | NCT04031742 | Sep 2019 → Dec 2021 | homozygous familial hypercholesterolemia | Innovent Biologics (Suzhou) Co. Ltd. | Completed | No outcome recorded |
| Phase 38 trials | ||||||
| Phase 3 | NCT07686796 | Jan 2027 → Jan 2030 expected | rectal cancer | Guangdong Provincial People's Hospital | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07473960 | Apr → Sep 2026 expected | hyperlipoproteinemia | Innovent Biologics (Suzhou) Co. Ltd. | Recruiting | No outcome recorded |
| Phase 3 | NCT07256197 | Apr 2026 → Dec 2028 expected | aortic valve stenosis | Beijing Anzhen Hospital | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT04968509 | Mar 2024 → Dec 2027 expected | aortic valve stenosis | Beijing Anzhen Hospital | Recruiting | No outcome recorded |
| Phase 3 | NCT04709536 | Feb → Nov 2021 | hyperlipoproteinemia | Innovent Biologics (Suzhou) Co. Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT04759534 | Sep 2020 → Oct 2021 | hypercholesterolemia, autosomal dominant, 3 | Shenzhen People's Hospital | Unknown | No outcome recorded |
| Phase 3 | NCT04289285 | Apr 2020 → Feb 2022 | hyperlipidemia | Innovent Biologics (Suzhou) Co. Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT04179669 | Dec 2019 → Jun 2021 | familial hypercholesterolemia | Innovent Biologics (Suzhou) Co. Ltd. | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT06683131 | Nov 2025 → Nov 2027 expected | acute myocardial infarction | The Affiliated Hospital of Xuzhou Medical University | Not yet recruiting | No outcome recorded |
| Phase not applicable2 trials | ||||||
| — | NCT07341958 | Feb → Dec 2026 expected | ischemic stroke | Beijing Tiantan Hospital | Not yet recruiting | No outcome recorded |
| — | NCT06096909 | Nov 2023 → Nov 2025 overdue | acute coronary syndrome | China National Center for Cardiovascular Diseases | Not yet recruiting | No outcome recorded |
Also used as a comparator or background therapy in 2 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03366688 Comparator | Nov 2017 → Nov 2018 | hyperlipidemia | Innovent Biologics (Suzhou) Co. Ltd. | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT05457582 Comparator | Mar 2023 → Sep 2026 expected | acute coronary syndrome, hyperlipidemia | Nanjing First Hospital, Nanjing Medical University | Recruiting | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 23 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | tafolecimab | “Sixty patients with hypercholesterolemia (phase 1b) were randomized to receive 75 or 140 mg tafolecimab every 2 weeks, 300 or 420 mg every 4 weeks, or 450 or 600 mg every 6...” PMID 36341216 ↗ Nov 202113“Patients in experimental group are treated with PCSK9 inhibitors (150mg Tafolecimab subcutaneously every two weeks) and guideline-directed management in cardiovascular primary...” NCT07256197 ↗ “Patients in experimental group are treated with PCSK9 inhibitors (140mg with Evolocumab or 75mg with Alirocumab or 150mg with Tafolecimab subcutaneously every two weeks)” NCT04968509 ↗ “Tafolecimab is a novel fully human proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibody, developed for the treatment of hypercholesterolemia.” PMID 37614541 ↗ Jul 2023 “Alirocumab was used before June 10, 2025; Tafolecimab has been used from June 10, 2025 onward.” NCT05457582 ↗ “PD-1 inhibitor (Sintilimab) and PCSK9 inhibitor (Tafolecimab)” NCT06304987 ↗ |
| Known as | IBI306 | “IBI306 is a fully human monoclonal antibody that binds proprotein convertase substilisin/kexin type 9 (PCSK9)” NCT03366688 ↗8“IBI306 is a kind of protein convertase subtilisin/kexin type 9 inhibitor.” NCT04759534 ↗ |
| Action | Inhibit | “preventing its interaction with the low-density lipoprotein cholesterol receptor (LDL-R)” NCT03366688 ↗ |
| Modality | Monoclonal antibody | “fully human monoclonal antibody” NCT03366688 ↗ |
| Route | Intravenous | “Subcutaneous or intravenous injection of a single dose of IBI306” NCT03366688 ↗ |
| Route | Subcutaneous | “Subcutaneous or intravenous injection of a single dose of IBI306” NCT03366688 ↗ |
| Target | PCSK9 | “binds proprotein convertase substilisin/kexin type 9 (PCSK9)” NCT03366688 ↗ |